... is a platelet aggregation inhibitor. It acts as a reversible cyclooxygenase inhibitor. The Merck Index (12th ed.). p ...

... is a platelet aggregation inhibitor. It works as a thromboxane synthase inhibitor and a thromboxane receptor ... inhibitor, the latter by modifying cellular responses to activation of the thromboxane receptor. Picotamide is licensed in ...

... is a platelet aggregation inhibitor. Orefice G, Grasso A, Fazio N, Del Vecchio G, Volpe G, Coppola M, D'Alessio A, ...

... platelet aggregation inhibitors, which prevent the formation of blood clots; and other anticoagulants. These compounds in their ...

Potent Inhibitors of the Aggregation of Human Platelets". Planta Medica. 51 (4): 300-303. doi:10.1055/s-2007-969496. PMID ...

... is an antispasmodic, vasodilator, and platelet aggregation inhibitor. Grignard addition of benzylmagnesiumbromide to ...

"Design and Synthesis of Piperidine-3-carboxamides as Human Platelet Aggregation Inhibitors". Journal of Medicinal Chemistry. 38 ...

... constitutes an antithrombotic, specifically an inhibitor of platelet aggregation. Tirofiban is a modified version of ... Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin ... non-peptide inhibitor of the interaction of fibrinogen with the integrin glycoprotein IIb/IIIa on human platelets. The Merck ... Lazarovici P, Marcinkiewicz C, Lelkes PI (May 2019). "From snake venom's disintegrins and C-type lectins to anti-platelet drugs ...

Fabian, K; Anke, T; Sterner, O (2001). "Mariannaepyrone--a new inhibitor of thrombroxane A2 induced platelet aggregation". ... elegans induces the aggregation of human platelet cells. M. elegans may also be consumed by amoebae. Bisette, John (1979). " ...

Cinnamtannin B-1 as an antioxidant and platelet aggregation inhibitor. Life sciences, 82(19), 977-982. doi:10.1016/j.lfs. ... and ability to inhibit platelet aggregation, which could contribute to the protection of damaged tissues in wounds. Anderson; ...

... the most potent inhibitor of platelet aggregation. More importantly, PGI2 (and not nitrous oxide) is also associated with an ... "Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil". Journal of Cardiovascular ... though it prolongs bleeding time by inhibiting collagen-induced platelet aggregation. Another drug, Milrinone, a Type 3 PDE-i ... Phosphodiesterase inhibitors (PDE-i) have been employed with excellent results. It has been shown to reduce mean PAP by as much ...

It acts as a platelet aggregation inhibitor by antagonising the P2Y12 receptor. The drug is produced by AstraZeneca. The most ... Inhibitors of the liver enzyme CYP3A4, such as ketoconazole and possibly grapefruit juice, increase blood plasma levels of ... Ticagrelor is a weak CYP3A4 inhibitor and is known to increase the concentrations of CYP3A4 metabolised medications; however, ... inhibitors and moderate or severe hepatic impairment due to the risk of increased exposure to ticagrelor. The common adverse ...

In molecular biology, ornatin is a potent glycoprotein IIb-IIIa (GP IIb-IIIa) antagonist and platelet aggregation inhibitor ... potent glycoprotein IIb-IIIa antagonists and platelet aggregation inhibitors from the leech Placobdella ornata". Eur. J. ...

Hawkey C (November 1967). "Inhibitor of platelet aggregation present in saliva of the vampire bat Desmodus rotundus". British ...

... a new platelet aggregation inhibitor produced by Penicillium herquei Fg-372". The Journal of Antibiotics. 49 (1): 50-3. doi: ... a New Platelet Aggregation Inhibitor Produced by Penicillium herquei Fg-372". ChemInform. 27 (27): no. doi:10.1002/chin. ...

This diverse range of compounds may include inhibitors of platelet aggregation, ADP, arachidonic acid, thrombin, and PAF; ... Additionally, Ixolaris, a tissue factor inhibitor, has been shown to block primary tumor growth and angiogenesis in a ... Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J. Thromb. Haemost. ... Tick saliva is a potent inhibitor of endothelial cell proliferation and angiogenesis. Thromb. Haemost. 94, 167e174. Maritz- ...

... is a phosphodiesterase 3 inhibitor which works by inhibiting platelet aggregation and dilating arteries. Cilostazol ... The proton pump inhibitor omeprazole, an inhibitor of CYP2C19, increases exposure to the active metabolite of cilostazol. A ... which is directly related with an inhibition in platelet aggregation. PKA also prevents the activation of an enzyme (myosin ... Serious side effects may include decreased survival in those with heart failure, low platelets, and low white blood cells. ...

Kistrin is a protein inhibitor of platelet aggregation. It belongs to the homologous family of glycoprotein IIb-IIa antagonists ... but platelet aggregation must grow exponentially to form a platelet thrombus and prevent blood loss. Platelet aggregation ... Some thromboregulators enhance platelet aggregation and some others inhibit the process. Platelet aggregation plays a critical ... These inhibitors are substances that prevent the clot formation by preventing platelet adhesion. Platelet inhibition is ...

Carbasalate calcium is an analgesic, antipyretic, and anti-inflammatory drug, as well as a platelet aggregation inhibitor. It ...

PGD2 is also involved in smooth muscle contraction/relaxation and is a potent inhibitor of platelet aggregation. This gene is ...

... common origins for blood coagulation and platelet aggregation inhibitors from soft ticks of the genus Ornithodoros". Molecular ... it inserts its hypostome and prevents the blood from clotting by excreting an anticoagulant or platelet aggregation inhibitor. ...

It is also a platelet aggregation inhibitor which is marketed in Spain and Portugal under the trade name Ageroplas. "Ditazole ...

... a potent inhibitor of platelet aggregation from Echis carinatus: synthesis and biological activity of selected analogs". Proc. ...

What had been shown was that they were potent inhibitors of ADP-induced platelet aggregation, but the P2Y12 receptor had not ... Ticagrelor is a much more potent inhibitor of platelet aggregation than clopidogrel, however, it is associated with increase of ... Activation of platelets and the subsequent aggregation of platelets has a crucial role maintaining normal haemostasis. ... When a vessel is damaged ADP is released from damaged cells and activated platelets, inducing further platelet aggregation. The ...

... is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised ... which in turn regulates the expression of the mRNA of the vascular cell adhesion molecule-1 needed for platelet aggregation. ... and thus preventing platelet aggregation preserves vascular prostacyclin, thus promoting anti-aggregant effect inhibits ... which regulates the expression of the mRNA of vascular cell adhesion molecule-1 needed for platelet aggregation blocks ...

Aggregation of platelets is highly regulated by cyclic nucleotides. PDE3A is a regulator of this process, and PDE3 inhibitors ... vascular smooth muscle and platelet aggregation. PDE3 inhibitors have been developed as pharmaceuticals, but their use is ... Cilostazol is approved for treatment of intermittent claudication and is thought to involve inhibition of platelet aggregation ... Electronic charges conserve the net charge overall and across the transition state PDE3 inhibitors: antagonize platelet ...

... platelet aggregation inhibitors (most notably apyrase, collagenase, and calin), vasodilators, and proteinase inhibitors. It is ... Inhibition of platelet aggregation and of leukocyte activity and examination of reputed anaesthetic effects". Comparative ... Montinari MR, Minelli S (May 2022). "From ancient leech to direct thrombin inhibitors and beyond: New from old". Biomedicine & ...

... which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following ... Glycoprotein IIb/IIIa inhibitors, Oximes, Piperidines, Prodrugs, All stub articles, Blood and blood forming organ drug stubs). ...

... inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. ... Angiolillo DJ, Capranzano P (August 2008). "Pharmacology of emerging novel platelet inhibitors". American Heart Journal. 156 (2 ... reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a ... impaired platelet turnover, and lung sequestration or apoptosis of overloaded destructive platelets. The dyspnea risks ...

"Commonly cited absolute contraindications to SWL include pregnancy, coagulopathy or use of platelet aggregation inhibitors, ...